Betta Pharmaceuticals' Ensartinib Wins NMPA Approval for Post-Surgical Adjuvant Treatment in ALK-Positive NSCLC, Achieving 86.4% Two-Year Disease-Free Survival Rate

Betta Pharmaceuticals, a Chinese pharmaceutical company, announced on September 3 that it has received a Drug Registration Certificate from China's National Medical Products Administration (NMPA) for ensartinib hydrochloride capsules, approving a new indication for post-surgical adjuvant treatment of ALK-positive Stage IB to IIIB non-small cell lung cancer (NSCLC).

This marks the third approved indication for ensartinib hydrochloride capsules. The next-generation anaplastic lymphoma kinase (ALK) inhibitor had previously received approval for both second-line and first-line treatment indications, expanding its therapeutic footprint in lung cancer care.

Clinical data from the post-surgical adjuvant treatment study demonstrated a two-year disease-free survival rate of 86.4%, according to the company's filing. The results also showed that the drug reduced the risk of disease recurrence by 80% compared to the control group, positioning ensartinib as a significant advancement in adjuvant therapy for early-stage lung cancer patients.

The approval represents a meaningful expansion of treatment options for patients who have undergone surgical resection for ALK-positive NSCLC, one of the most aggressive subtypes of lung cancer. ALK gene rearrangements occur in approximately 3% to 5% of all NSCLC cases, but tend to affect younger patients and those with less smoking history.

The adjuvant setting has become a critical battleground in lung cancer treatment, as preventing recurrence after surgery can significantly improve long-term survival outcomes. With an 86.4% disease-free survival rate at two years and an 80% reduction in recurrence risk, ensartinib's profile positions it competitively in this therapeutic space.

Betta Pharmaceuticals, headquartered in Hangzhou, Zhejiang Province, has built its portfolio around targeted cancer therapies. The company's focus on precision medicine aligns with the broader industry trend toward biomarker-driven treatment approaches in oncology.